Ooyama Akio, Okayama Yoshihiro, Takechi Teiji, Sugimoto Yoshikazu, Oka Toshinori, Fukushima Masakazu
Personalized Medicine Research Laboratory, Taiho Pharmaceutical Co., 224-2 Ebisuno, Hiraishi, Kawauchi-cho Tokushima, 711-0194, Japan.
Cancer Sci. 2007 Apr;98(4):577-83. doi: 10.1111/j.1349-7006.2007.00424.x.
Resistance to chemotherapeutic agents represents the chief cause of mortality in cancer patients with advanced disease. Chromosomal aberration and altered gene expression are the main genetic mechanisms of tumor chemoresistance. In this study, we have established an algorithm to calculate DNA copy number using the Affymetrix 10K array, and performed a genome-wide correlation analysis between DNA copy number and antitumor activity against 5-fluorouracil (5-FU)-based drugs (S-1, tegafur + uracil [UFT], 5'-DFUR and capecitabine) to screen for loci influencing drug resistance using 27 human cancer xenografts. A correlation analysis confirmed that the single nucleotide polymorphism (SNP) showing significant associations with drug sensitivity were concentrated in some cytogenetic regions (18p, 17p13.2, 17p12, 11q14.1, 11q11 and 11p11.12), and we identified some genes that have been indicated their relations to drug sensitivity. Among these regions, 18p11.32 at the location of the thymidylate synthase gene (TYMS) was strongly associated with resistance to 5-FU-based drugs. A change in copy number of the TYMS gene was reflected in the TYMS expression level, and showed a significant negative correlation with sensitivity against 5-FU-based drugs. These results suggest that amplification of the TYMS gene is associated with innate resistance, supporting the possibility that TYMS copy number might be a predictive marker of drug sensitivity to fluoropyrimidines. Further study is necessary to clarify the functional roles of other genes coded in significant cytogenetic regions. These promising data suggest that a comprehensive DNA copy number analysis might aid in the quest for optimal markers of drug response.
对化疗药物的耐药性是晚期癌症患者死亡的主要原因。染色体畸变和基因表达改变是肿瘤化疗耐药的主要遗传机制。在本研究中,我们建立了一种使用Affymetrix 10K芯片计算DNA拷贝数的算法,并对27个人类癌症异种移植模型进行了DNA拷贝数与针对基于5-氟尿嘧啶(5-FU)的药物(S-1、替加氟+尿嘧啶[UFT]、5'-去氧氟尿苷和卡培他滨)的抗肿瘤活性之间的全基因组相关性分析,以筛选影响耐药性的基因座。相关性分析证实,与药物敏感性显著相关的单核苷酸多态性(SNP)集中在一些细胞遗传学区域(18p、17p13.2、17p12、11q14.1、11q11和11p11.12),并且我们鉴定了一些已表明与药物敏感性有关的基因。在这些区域中,胸苷酸合成酶基因(TYMS)所在位置的18p11.32与对基于5-FU的药物的耐药性密切相关。TYMS基因拷贝数的变化反映在TYMS表达水平上,并且与对基于5-FU的药物的敏感性呈显著负相关。这些结果表明,TYMS基因的扩增与先天性耐药有关,支持TYMS拷贝数可能是氟嘧啶类药物敏感性预测标志物的可能性。有必要进一步研究以阐明在重要细胞遗传学区域编码的其他基因的功能作用。这些有前景的数据表明,全面的DNA拷贝数分析可能有助于寻找最佳的药物反应标志物。